Allergan Valeant

Allergan board unanimously rejected Valeant’s unsolicited bid

Written by Joseph Nordqvist

Published: 11:45, June 23, 2014

The Allergan board unanimously rejected Valeant’s unsolicited bid, describing the offer as “grossly inadequate”, and added that it substantially undervalues the company, and is not in the best interests of the company and its shareholders.

The Board of the California-based Botox maker urged Allergan stockholders not to offer their stocks to Valeant.

In a statement, Allergan said its advisers BofA Merrill Lynch and Goldman Sachs & Co said that from a financial point of view the offer was “inadequate”.

Allergan had previously rejected a Valeant offer of $52 billion plus stock. A joint bid to acquire the company had been made by William Ackman, an activist investor who owns 9.7% of Allergan, together with Valeant.

Valeant share price sliding

The previous offer consisted of $72 in cash plus 0.82 Valeant shares, making it worth about $177 per share. Allergan pointed out that as Valeant’s share price has declined since then, the offer now has dropped to approximately $173.20 per share.

David E.I. Pyott, Allergan’s Chairman of the Board and Chief Executive Officer, said today:

“Our Board is unanimous in its determination that Valeant’s unsolicited exchange offer is grossly inadequate, substantially undervalues Allergan, and is not in the best interests of Allergan and its stockholders. The Board strongly recommends that Allergan stockholders reject Valeant’s exchange offer and prevent Valeant from taking control of Allergan at a price that does not appropriately reflect the underlying value of Allergan’s assets.”

“Allergan has a track record of consistently acting in the best interests of its stockholders and the Board continues to be confident that Allergan will create significantly more value than Valeant’s proposal.”

Mr. Pyott derided Valeant for not taking into account Allergan’s:

  • growth prospects,
  • exceptional management,
  • strong balance sheet,
  • financial performance, and
  • industry-leading position.

Allergan explained that its goal is to expand adjusted earnings by between 20 to 25 cents a share and build up $14 billion in free cash flow by 2019.

Allergan criticizes Valeant’s business model

Allergan made the following comments about Valeant:

  • Valeant’s growth, based on acquisitions, is unsustainable.
  • Valeant’s growth is anemic and depends on unsustainable price increases.
  • Valeant’s projected synergy claims “are aggressive”.
  • Valeant grossly under-invests, a behavior that would put the Botox maker’s core business at risk if Valeant took over.
  • Valeant is less transparent in its financial statements than either Allergen or its industry peers are.
  • “Valeant’s R&D capabilities pale when compared to Allergan’s track record of innovation and value creation.”

Allergan too research-based, says Valeant

Valeant says Allergan spends too much on R&D of drugs. It insists that if the two companies integrated, costs would be reduced and sales increased.

Valeant hardly spends anything on R&D, preferring to buy companies with proven treatments. However, it tends to then severely strip down the research departments in the newly-acquired firms.

In 2012, Valeant took over Medicis Pharmaceutical Corp. After the acquisition, Medicis employees were assembled and handed envelopes. Those who received black envelopes were fired. The majority of Medici’s R&D department employees received black envelopes. Soon, Medici’s thirty research projects were all cancelled.

Allergan rejects Valeant bid

Who will win in the end? Research-based or acquisition-driven enterprises?

This strategy, of buying companies with successful products and trimming their R&D departments right down has worked as far as Valeant’s CEO, Michael Pearson is concerned. From 2008 to 2013, his company’s annual sales increased six-fold to $5.8 billion, and the company’s shares have risen in value by 848%.

On Monday, Valeant, based in Laval, Québec, Canada, posted a 10-page rebuttal online to criticisms by Allergan.

Laurie Little, a Valeant spokesperson, said:

“Allergan’s rejection of Valeant’s proposal is based on beliefs and assumptions about our business that are not supported by the facts. We are moving forward with our exchange offer and remain committed to this value-creating transaction.”

Joseph Nordqvist Avatar

Other News

What virtual shopping tools can change before and after a purchase

Nov 19, 2026

Game-like loyalty features drew more engagement in an online grocery study

Nov 18, 2026

A delivery cue helped more shoppers move to the next checkout step

Nov 18, 2026

Small changes in a store can bring promotions back to repeat customers’ attention

Nov 18, 2026

Some sellers accept less when a buyer shares an item’s heritage

Nov 18, 2026

Changing a marketplace trust badge can change what sellers prioritize

Nov 18, 2026

Referred customers may bring in more customers of their own

Nov 18, 2026

An extra option can make an attractive menu less appealing, experiments find

Nov 17, 2026

Adding similar choices can change which products look like the middle option

Nov 17, 2026

World Bank plans e-commerce pilot for small firms in three West African countries

Nov 17, 2026

Contextual ads were the most common targeting method among EU online advertisers

Nov 17, 2026

People treat the same money differently across spending categories, study finds

Nov 17, 2026

Small-business loan applications can stall before they are formally submitted

Nov 17, 2026

Describing the parts of an experience can change how much people enjoy it

Nov 16, 2026

A prize can feel different when customers know they might have received less

Nov 16, 2026

Frequent rating requests can change how customers experience a service

Nov 16, 2026

How a business handles customer data can shape its relationship with buyers

Nov 16, 2026

Trying a customized product can shape what shoppers choose later

Nov 16, 2026

Why the way unit prices are shown can change how shoppers judge a deal

Nov 16, 2026

Why the weather can affect ratings of cold-weather gear

Nov 15, 2026